MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Danaher Acquires Swiss Life Sciences Software Firm Genedata

NextEdge Admin

19 Aug 2024

1 min 56 sec

Danaher has acquired Swiss life science informatics firm Genedata, expanding its capabilities in drug discovery, development, and manufacturing. The financial details of the transaction were not disclosed.

Based in Basel, Genedata provides specialized software for the biopharma R&D sector, focusing on automating and managing data processes across various technologies. Notable products include Genedata Selector, which facilitates next-generation sequencing-based cell line development, and Genedata Expressionist, tailored for mass spectrometry workflows.

Othmar Pfannes, Genedata's founder and CEO, described the firm as a global leader in digitalizing R&D processes to accelerate the delivery of personalized medicines. He emphasized that as a Danaher operating company, Genedata will continue to attract top talent and tackle the most challenging problems faced by its customers worldwide.

Greg Milosevich, Vice President and Group Executive of Danaher's DH Life Sciences subsidiary, acknowledged the long-standing partnership between the two companies. He praised Genedata's innovative software, which is deeply rooted in scientific expertise, and noted the shared commitment to helping biopharma companies accelerate the development of critical therapies by providing researchers with high-quality insights.

The acquisition strengthens Danaher's position in the biopharma industry, building on their existing collaborations and shared mission to advance R&D processes.